Granules India Limited · NSE:GRANULES
Granules India — Q2 FY22 Earnings Presentation
16 slides from Granules India's earnings presentation, Nov 12, 2021
Slide 1: Exchange filing cover letter: presentation to analysts/investors
G GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, India. Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLC012471 Dated November 12, 2021 To, National Stock Exchan
Slide 2: Granules India Limited Q2 & H1FY22 Earnings Presentation
Granules India Limited Q2 & H1FY22 Earnings Presentation
Slide 3: Safe Harbor
Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 4: Q2 FY22 Financial Highlights
Q2 FY22 Financial Highlights (In ₹ Mn) Income from Operations (Rs. Mn.) Gross margin and margin% (Rs. Mn.) EBITDA and EBITDA margins(Rs. Mn.) 3.52% 4,970 4,517 8,581 8,883 2,564 57.9% 50.9% 1,512 29.9% 17.0% Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 PAT (Rs. Mn.) EPS (In Rs.) • Income growth d
Slide 5: Geographical Mix
Q2FY22 Revenue spilt by Market, Molecules and Segments (In ₹ Mn) Growth momentum witnessed in North America Finished Dosage and PFI segments grew 18% and 10% 8,883 57.20% 8,581 55.00% 8,581 8,883 FD PFI Segment Revenue 4,301 5,066 Geographical Mix API 20.40% 17.90% 1,733 13.80% 11.00% 1,912 7.70% 7.
Slide 6: Q2FY22 Key Financial and Business Highlights
Q2FY22- Key Financial and Business Highlights Granules Q2 business was unfavourably impacted due to difficulties in procuring Raw materials, mainly from China due to Chinese dual energy policy and increased procurement prices for almost all items due to interruptions in supply of materials and inc
Slide 7: Q2 FY22 Financial Ratios
Q2 FY22 Financial Ratios (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Operational Cash Flow Free Cash Flow * 522 506 1,453 6,298 6,576 1,328 324 6,133 6,121 0.9 5,752 1,123 214 0.8 1,005 928 0.7 0.7 0.7 -302 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q2 FY21 Q3 FY
Slide 8: 5 years Revenue – Contribution from Core vs Other Molecules
5 years Revenue – Contribution from Core vs Other Molecules Others Core FY17 FY18 FY19 FY20 FY21 14% 14% 17% 15% 16% 18% 3% 34% 16% 26% 3% 5% 25% 15% 29% 23% 3% 6% 19% 17% 33% 21% 86% 86% 83% 85% 84% 4% 17% 14% 34% 29% 1% 5% 34% 30% 14% 14% 5% 3% FY17 FY18 FY19 FY20 FY21 Para MF IBU GGF MCB Others C
Slide 9: ANDA/Dossier filing status as of Sep'21
ANDA/Dossier filing status as of Sep’21 GPI IP GIL IP Filing Status Total USA USA Europe Canada South Africa UK Approved 20 24 2 2 48 Tentatively Approved 1 1 2 To be approved 7 5 5 1 2 2 22 Total Products 28 30 7 3 2 2 72 Total GPI products include: CII – 7 PFOS – 4 Liquid Orals - 3 IMS value for t
Slide 10: Improving returns; focus on OCF generation for funding capex
Improving returns; focus on OCF generation for funding capex while meeting increased working capital requirement: 5-year trajectory (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) 2,919 135 9,082 125 1,615 8,704 114 117 109 3.1 6,138 6,058 5,752 -172 2.4 2.
Slide 11: 5-year trajectory: Creating value for stakeholders
5-year trajectory: Creating value for stakeholders (In ₹Mn) Revenue - 5-year CAGR 19% Gross Profit & Gross Margin - 5-year CAGR 23% 32,375 18,463 25,986 22,792 13,177 57.0% 16,918 10,236 14,353 7,556 7,955 50.7% 52.6% 44.9% 47.0% FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 EBITDA* & EBITDA Mar
Slide 12: Increasing share from FDs while focusing on backward integration
Increasing share from FDs while focusing on backward integration (In ₹Mn) Higher revenue contribution coming from regulated market, 72% of total revenues Total Revenue 14,353 16,918 22,792 25,986 32,375 17,451 13,879 11,113 6,010 6,612 5,055 5,674 4,083 4,029 4,573 3,795 4,525 3,550 2,650 3,367 2,92
Slide 13: ESG Journey - Granules
ESG Journey - Granules Highest in Pharma Median in Pharma Lowest in Pharma Granules 80 68 69 63 59 57 52 52 53 53 45 44 41 37 36 31 Environmental Social Governance Overall Source: S&P Global CRISIL Ranking Our efforts have been recognized by CRISIL, an S&P Global company, with a healthy score among
Slide 14: In Summary
In Summary Timely launches of products expected FY22 Focus on Cash conservation and liquidity while increasing the market share of existing management products by passing on cost benefits realized Focus on Free cash flow generation and reduction in through operational efficiencies net debt Improve p
Slide 15: Glossary
Glossary API: Active Pharmaceutical Ingredient PFI: Pharmaceuticals Formulation Intermediates FD: Finished Dosage OTC: Over the counter drugs Rx: Prescription drugs IR: Immediate Release ER: Extended Release CII: Control substances PFOS: Powder for oral suspensions and solutions MUPS: Multi-unit pel
Slide 16: Contact details
Mr. Krishna Raghunathan VP Finance and Investor Relations Email: krishna.raghunathan@granulesindia.com www.granulesindia.com Ms. Payal Dave payal.dave@linkintime.co.in Ms. Neha Shroff +91 7738073466 neha.shroff@linkintime.co.in www.orientcap.com 532482 GRANULES Corporate address: GRAN:IN Floor 2 Blo